Abstract #1131

A fluorine-19 MR characterization of ABL-101 - a novel tracer with high biocompatibility and MR sensitivity

Emeline Darçot¹, Roberto Colotti¹, David Brennan^2,3, Graeme A Deuchar³, Celestine Santosh^2,3, and Ruud B van Heeswijk^1,4

¹Radiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ²Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom, ³Aurum Biosciences Ltd, Glasgow, United Kingdom, ⁴Center for BioMedical Imaging (CIBM), Lausanne and Geneva, Switzerland

A major challenge that slows down the translation of fluorine-19 (¹⁹F) MRI for inflammation monitoring and cell tracking into clinical practice is the need for perfluorocarbons (PFCs) that have good biocompatibility while also being suitable for ¹⁹F MRI. We therefore characterized ABL-101, a perfluoro(t-butylcyclohexane) emulsion, as a ¹⁹F MRI tracer. ABL-101 had T₂/T₁ ratios and detection limits similar to PFCs developed specifically for MRI. This combined with the short clearance half-life of this intravenous emulsion make ABL-101 a very promising candidate as a tracer in future clinical trials that use ¹⁹F MRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here